Abstract | BACKGROUND: METHODS: RESULTS: A total of 304 patients were randomly assigned to receive posaconazole, and 298 patients were randomly assigned to receive fluconazole (240) or itraconazole (58). Proven or probable invasive fungal infections were reported in 7 patients (2%) in the posaconazole group and 25 patients (8%) in the fluconazole or itraconazole group (absolute reduction in the posaconazole group, -6%; 95% confidence interval, -9.7 to -2.5%; P<0.001), fulfilling statistical criteria for superiority. Significantly fewer patients in the posaconazole group had invasive aspergillosis (2 [1%] vs. 20 [7%], P<0.001). Survival was significantly longer among recipients of posaconazole than among recipients of fluconazole or itraconazole (P=0.04). Serious adverse events possibly or probably related to treatment were reported by 19 patients (6%) in the posaconazole group and 6 patients (2%) in the fluconazole or itraconazole group (P=0.01). The most common treatment-related adverse events in both groups were gastrointestinal tract disturbances. CONCLUSIONS:
|
Authors | Oliver A Cornely, Johan Maertens, Drew J Winston, John Perfect, Andrew J Ullmann, Thomas J Walsh, David Helfgott, Jerzy Holowiecki, Dick Stockelberg, Yeow-Tee Goh, Mario Petrini, Cathy Hardalo, Ramachandran Suresh, David Angulo-Gonzalez |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 356
Issue 4
Pg. 348-59
(Jan 25 2007)
ISSN: 1533-4406 [Electronic] United States |
PMID | 17251531
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2007 Massachusetts Medical Society. |
Chemical References |
- Antifungal Agents
- Antineoplastic Agents
- Triazoles
- Itraconazole
- posaconazole
- Fluconazole
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antifungal Agents
(adverse effects, therapeutic use)
- Antineoplastic Agents
(adverse effects)
- Female
- Fluconazole
(adverse effects, therapeutic use)
- Humans
- Itraconazole
(adverse effects, therapeutic use)
- Kaplan-Meier Estimate
- Leukemia, Myeloid, Acute
(complications, drug therapy, mortality)
- Male
- Middle Aged
- Mycoses
(mortality, prevention & control)
- Myelodysplastic Syndromes
(complications, drug therapy, mortality)
- Neutropenia
(chemically induced, drug therapy, mortality)
- Opportunistic Infections
(prevention & control)
- Single-Blind Method
- Treatment Outcome
- Triazoles
(adverse effects, therapeutic use)
|